Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma
Language English Country Great Britain, England Media print
Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- MeSH
- Asthma complications drug therapy pathology MeSH
- Adult MeSH
- Eosinophilia complications drug therapy pathology MeSH
- Eosinophils drug effects pathology MeSH
- Adrenal Cortex Hormones administration & dosage therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Prospective Studies MeSH
- Sputum cytology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Names of Substances
- Adrenal Cortex Hormones MeSH
Under Global Initiative for Asthma guidelines, the clinical control of disease activity and the adjustment of treatment in patients with asthma are based on symptoms, use of rescue medication, lung function and peak expiratory flow measurement (standard strategy). We investigated whether a strategy to reduce the number of sputum eosinophils (EOS strategy) gives better clinical control and a lower exacerbation rate compared with the standard strategy. Fifty-five patients with moderate to severe asthma entered this open, randomized, parallel-group study and visited the out-patient department every 3 months for 18 months. The dose of corticosteroids was adjusted according to the standard strategy or the percentage of sputum eosinophils (EOS strategy). During the study period, the EOS strategy led to a significantly lower incidence of asthma exacerbations compared with the standard strategy group (0.22 and 0.78 exacerbations per year per patient, respectively). There were significant differences between the strategies in time to first exacerbation.
References provided by Crossref.org
Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment
